Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) plus Ctx versus trastuzumab (T) plus Ctx in patients (pts) with pretreated HER2+metastatic (met) breast cancer (MBC). Escriva, S., Im, S., Cardoso, F., Cortes, J., Curigliano, G., Gradishar, W., Pegram, M. D., Wright, G., Levy, C., De laurentiis, M., Ferrero, J., Bahadur, S., Kim, S., Petrakova, K., Riseberg, D. A., Yardley, D. A., Edlich, S., Hong, S., Rock, E. P., Rugo, H. S. AMER SOC CLINICAL ONCOLOGY. 2020
View details for Web of Science ID 000560368300210